GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » Buyback Yield %

Lumos Diagnostics Holdings (ASX:LDX) Buyback Yield % : -48.49 (As of Jun. 19, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Lumos Diagnostics Holdings's current buyback yield was -48.49%.


Lumos Diagnostics Holdings Buyback Yield % Historical Data

The historical data trend for Lumos Diagnostics Holdings's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings Buyback Yield % Chart

Lumos Diagnostics Holdings Annual Data
Trend Jun22 Jun23
Buyback Yield %
-38.11 -

Lumos Diagnostics Holdings Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Buyback Yield % Get a 7-Day Free Trial 24.35 -202.10 - - -44.34

Competitive Comparison of Lumos Diagnostics Holdings's Buyback Yield %

For the Diagnostics & Research subindustry, Lumos Diagnostics Holdings's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lumos Diagnostics Holdings's Buyback Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Lumos Diagnostics Holdings's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Lumos Diagnostics Holdings's Buyback Yield % falls into.



Lumos Diagnostics Holdings Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Lumos Diagnostics Holdings's Buyback Yield for the fiscal year that ended in Jun. 2023 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 3.0942
=0.00%

Lumos Diagnostics Holdings's annualized Buyback Yield for the quarter that ended in Dec. 2023 is calculated as

Buyback Yield=Net Issuance of Stock(Annualized) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) * Annualized Factor / Market Cap
=- (-0.527 + 7.996) * 2 / 33.691
=-44.34%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the annualized semi-annual data, the Repurchase of Stock and Issuance of Stock data used here is two times the semi-annual (Dec. 2023) data.


Lumos Diagnostics Holdings Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lumos Diagnostics Holdings (ASX:LDX) Business Description

Traded in Other Exchanges
Address
2724 Loker Ave West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings (ASX:LDX) Headlines

No Headlines